ROMY 250

Romy 250 mcg Injection is a platelet-stimulating agent containing the active ingredient Romiplostim. It is used in the treatment of immune primary thrombocytopenia (ITP)—a condition in which the immune system mistakenly destroys the body’s own platelets, leading to abnormally low platelet counts. This injection is prescribed primarily for adults and children aged 18 years and older with ITP who have not responded adequately to prior treatments such as corticosteroids, immunoglobulins, or splenectomy (surgical removal of the spleen).

Romy 250 mcg is contraindicated in individuals with a known hypersensitivity to Romiplostim or to other medications produced using Escherichia coli (E. coli) DNA technology. Before beginning treatment, inform your physician if you have a history of liver disease, cancer, recent surgeries, smoking, or if you are taking hormonal contraceptives, as these factors may influence treatment safety and effectiveness.

Regular blood monitoring is required during treatment to detect potential bone marrow abnormalities, which have been associated with Romiplostim. If such changes are found, your doctor will assess their significance and decide whether to continue or discontinue the therapy.

This medication is not recommended during pregnancy unless clearly indicated by your doctor. Inform your healthcare provider if you are pregnant, planning to become pregnant, or suspect pregnancy before starting treatment. It is unknown whether Romiplostim passes into breast milk, so breastfeeding should be avoided while on this medication unless advised otherwise by your physician